Covariates were all variables expected to be associated with mini‐consolidations versus IDAC (age, gender, performance status, WBC, 2017 ELN risk, secondary versus de novo AML, NPM1 and FLT3‐ITD mutations, study period, history of cytotoxic treatment, and targeted therapy added to induction and inclusion in a clinical trial). The gene discussed is FLT3; the disease is acute myeloid leukemia.